

Rec'd PTO 17 AUG 2005
10/517137
PATENT APPLICATION
#4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q84960

Rian VAN MEETEREN, et al.

Appln. No.: 10/517,137

Group Art Unit: Unknown

Confirmation No.: 6831

Examiner: Unknown

Filed: December 07, 2004

For: OVERACTIVE BLADDER TREATING DRUG

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 and 1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith, except for the following: U.S. patents and/or U.S. patent publications if this application was filed after June 30, 2003; and co-pending non-provisional U.S. applications filed after June 30, 2003.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after

INFORMATION DISCLOSURE STATEMENT
U.S. Appln. No.: 10/517,137
Attorney Docket No.: Q84960


filings a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

In compliance with the concise explanation requirement under 37 C.F.R. § 1.98(a)(3) for foreign language documents, Applicant encloses herewith a copy of a Communication from a foreign patent office in a counterpart application citing such documents, together with an English-language version (if not already included) of at least that portion of the Communication indicating the degree of relevance found by the foreign patent office. In addition, foreign language documents are discussed at pages 1-2 in the present specification.

Also, translations of foreign language documents are submitted herewith.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account. A duplicate copy of this paper is attached.

Respectfully submitted,

Mark Boland / *Brant L. Kramer*
Mark Boland
Registration No. 32,197

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE
23373
CUSTOMER NUMBER

Date: August 17, 2005

Substitute for Form 1449 A & B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known	
Application Number	10/517,137
Confirmation Number	6831
Filing Date	December 07, 2004
First Named Inventor	Rian VAN MEETEREN
Art Unit	Unknown
Examiner Name	
Attorney Docket Number	Q84960

Sheet

1

of

1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		
	US				

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)			
	EP	801 067	A1	10-15-1997	Yamanouchi Pharmaceutical Co., Ltd.		
	WO	96/38143	A1	12-05-1996	Synaptic Pharmaceutical Corp.		
	WO	99/57131	A1	11-11-1999	Duke University		
	EP	34 432	A2	08-26-1981	Yamanouchi Pharmaceutical Co. Ltd.		
	EP	1 088 551	A1	04-04-2001	Yamanouchi Pharmaceutical Co. Ltd		
	EP	1 203 582	A1	05-08-2002	Yamanouchi Pharmaceutical Co. Ltd.		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶
		SELLERS, Donna J. et al, "Potential therapeutic targets for the treatment of the overactive bladder", World Journal of Urology, vol. 19, no. 5, p307-311, 2001	
		SCARPA, R.M. "Lower Urinary tract symptoms: what are implications for the patients?" European Urology, vol. 40, suppl. 4, p12-20, 2001	
		Current Therapy, vol. 19, no. 12, p8-11, 2001, with English translation	
		Urology, vol. 55, suppl. 5a, p1-2, 2000	
		Medicines and Drug Journal, vol. 38, S-1, p283-288, 2002, with English translation	
		BJU International, vol. 85, suppl. 2, p6-11, 2000	
		Shinyaku-to-Rinsho, vol. 44, no. 8, p61-64, 1995, with English translation	
		BJU International, vol. 85, Suppl. 2, p25-30, 2000	
		Neurology and Urodynamics, vol. 17, No. 1, p31-36, 1998	
		European Urology, vol. 36, Suppl. 1, p89-95, 1999	
		European Urology Supplements, 2, No. 1, p171, 674, 2003	
		Japan Pharmaceutical Reference, Products and Administration in Japan, The Fifth Edition (1999), p1263-1265	
		AHFS Drug Information 2000, p3712-3713	

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to indicate here if English language Translation is attached.